FULGENT GENETICS, INC. Available-for-sale Securities, Gross Unrealized Loss
FULGENT GENETICS, INC. (FLGT) reported Available-for-sale Securities, Gross Unrealized Loss of $185.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2018-08-13
- FULGENT GENETICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2018-06-30 was -$62.00K.
- FULGENT GENETICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2018-03-31 was $247.00K, a 87.12% increase year-over-year.
- FULGENT GENETICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2017-12-31 was $74.00K.
- FULGENT GENETICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2017-09-30 was -$19.00K.
- FULGENT GENETICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2016 was $163.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $185.00K 10-Q · filed 2018-08-13 | $259.00K derived: sum of 3 quarters · filed 2018-08-13 | $240.00K derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $247.00K 10-Q · filed 2018-05-14 | $321.00K derived: sum of 2 quarters · filed 2018-08-13 | $302.00K derived: sum of 3 quarters · filed 2018-08-13 | $279.00K derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-12-31 | $74.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2018-08-13 | $55.00K derived: sum of 2 quarters · filed 2018-08-13 | $32.00K derived: sum of 3 quarters · filed 2018-08-13 | $164.00K 10-Q · filed 2018-08-13 |
| 2017-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$42.00K derived: sum of 2 quarters · filed 2017-11-13 | $90.00K 10-Q · filed 2017-11-13 | |
| 2017-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $109.00K 10-Q · filed 2017-08-14 | ||
| 2017-03-31 | $132.00K 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $163.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |